NASHVILLE, Tenn. , July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare...
Record Date is July 10, 2026 & Payment Date is July 31,2026
$100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland's Focus on Rare Disease Pipeline
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patients
Positive Results from Phase 2a Clinical Trial
Commercialization in China through partnership with SciClone Pharmaceuticals
Enters into Strategic Transaction, unlocking $100 million in value
NASHVILLE, Tenn. , April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that it will release its first quarter 2026...
Transaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical Needs